Tokyo Tape
Sign in
← Sakai Chemical Industry

Quarterly report · Q2

4078.TEDINET S100PH2A
Period2022-04-01 → 2022-09-30
Filed2022-11-09
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥42.7bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥80.1bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥39.9bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥3.3bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥4.4bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥3.8bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥8.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.6bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥4.2bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥4.5bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥2.9bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥6.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥3.2bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥3.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥3.3bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥128.4bnat 2022-09-30Cons.Assets
Total assets¥123.9bnat 2022-03-31Cons.Assets
Total assets¥124.5bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥42.6bnat 2022-09-30Cons.Liabilities
Total liabilities¥41.2bnat 2022-03-31Cons.Liabilities
Net assets / equity¥85.8bnat 2022-09-30Cons.Net assets
Net assets / equity¥82.7bnat 2022-03-31Cons.Net assets
Net assets / equity¥82.3bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥11.9bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥10.8bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥11.7bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥10.5bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥11.8bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥11.2bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥1.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥6.6bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.8bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.0bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥177.482022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.082022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥407.062021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥188.852021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥91.632021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio63.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio63.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio63.2%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥860m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥860m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2022-04-01 → 2022-09-30¥39.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2022-04-01 → 2022-09-30¥38.6bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥697m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2022-04-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥163m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2022-04-01 → 2022-09-30¥240m
—segment totalrevenue2022-04-01 → 2022-09-30¥43.6bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥42.7bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥860m
—segment totalsegment profit2022-04-01 → 2022-09-30¥4.4bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥684m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥684m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥977m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2021-04-01 → 2021-09-30¥36.4bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2021-04-01 → 2021-09-30¥35.8bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥548m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2021-04-01 → 2021-09-30¥5.1bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2021-04-01 → 2021-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2021-04-01 → 2021-09-30¥4.1bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥136m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2021-04-01 → 2021-09-30¥233m
—segment totalrevenue2021-04-01 → 2021-09-30¥40.6bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥39.9bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥684m
—segment totalsegment profit2021-04-01 → 2021-09-30¥5.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 510
ItemContextValueUnit
Other clPrior1YearInstant5836000000JPY
Other clCurrentQuarterInstant5305000000JPY
Current liabilitiesPrior1YearInstant26771000000JPY
Current liabilitiesCurrentQuarterInstant29130000000JPY
Long term loans payablePrior1YearInstant8756000000JPY
Long term loans payableCurrentQuarterInstant7715000000JPY
Provision for environmental measures nclPrior1YearInstant139000000JPY
Provision for environmental measures nclCurrentQuarterInstant142000000JPY
Net defined benefit liabilityPrior1YearInstant5190000000JPY
Net defined benefit liabilityCurrentQuarterInstant5204000000JPY
Deferred tax liabilitiesPrior1YearInstant76000000JPY
Deferred tax liabilitiesCurrentQuarterInstant125000000JPY
Other nclPrior1YearInstant277000000JPY
Other nclCurrentQuarterInstant242000000JPY
Noncurrent liabilitiesPrior1YearInstant14439000000JPY
Noncurrent liabilitiesCurrentQuarterInstant13429000000JPY
LiabilitiesPrior1YearInstant41211000000JPY
LiabilitiesCurrentQuarterInstant42559000000JPY
Capital stockPrior1YearInstant21838000000JPY
Capital stockCurrentQuarterInstant21838000000JPY
Capital surplusPrior1YearInstant16299000000JPY
Capital surplusCurrentQuarterInstant16293000000JPY
Retained earningsPrior1YearInstant41433000000JPY
Retained earningsCurrentQuarterInstant43738000000JPY
Treasury stockPrior1YearInstant-1798000000JPY
Treasury stockCurrentQuarterInstant-1751000000JPY
Shareholders equityPrior1YearInstant77772000000JPY
Shareholders equityCurrentQuarterInstant80119000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant1202000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant1057000000JPY
Deferred gains or losses on hedgesPrior1YearInstant6000000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant23000000JPY
Foreign currency translation adjustmentPrior1YearInstant-149000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant389000000JPY
Remeasurements of defined benefit plansPrior1YearInstant21000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant21000000JPY
Valuation and translation adjustmentsPrior1YearInstant1081000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant1491000000JPY
Non controlling interestsPrior1YearInstant3854000000JPY
Non controlling interestsCurrentQuarterInstant4191000000JPY
Net assetsPrior1YearInstant82708000000JPY
Net assetsCurrentQuarterInstant85803000000JPY
Liabilities and net assetsPrior1YearInstant123919000000JPY
Liabilities and net assetsCurrentQuarterInstant128362000000JPY
Net salesPrior1YTDDuration39905000000JPY
Net salesCurrentYTDDuration42694000000JPY
Cost of salesPrior1YTDDuration28942000000JPY
Cost of salesCurrentYTDDuration32311000000JPY
Gross profitPrior1YTDDuration10963000000JPY
Gross profitCurrentYTDDuration10383000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass